Autologous Point-of-Care Adipose Therapy: Recent Injury
Launched by UNIVERSITY OF PITTSBURGH · Feb 26, 2025
Trial Information
Current as of July 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new treatment method to help people who have suffered serious injuries, such as severe burns or wounds that require extensive repair. The researchers want to see if using a patient’s own fat (called adipose tissue) can improve healing and reduce scarring when applied directly to the wound right after an injury. Participants will receive this fat grafting along with a skin graft in a single procedure, and the study will compare this method with traditional healing techniques to determine which one works better.
To be eligible for this study, participants must be adults aged 18 or older, either male or female, and can include civilians, military personnel, or veterans. They should have significant injuries, like full-thickness skin loss from trauma or burns that need reconstruction. However, individuals with active infections, certain medical conditions, or those who are pregnant cannot participate. If you choose to join this study, you will receive immediate treatment that aims to improve your recovery experience. The trial is still in the planning stages and is not yet recruiting participants.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The proposed study will include adult patients 18 years of age or older,
- • male or female,
- • civilian, military, active duty or retired veterans
- • presenting for unilateral or bilateral fasciotomy of the extremity at any level necessary
- • secondary to non-infectious etiology,
- • unilateral or bilateral traumatic full-thickness skin loss of the face, head, neck or extremities necessitating reconstruction, and/or
- • full or partial thickness burn injury of the face, neck, or extremity requiring excision and/or reconstruction.
- • Additional inclusion criteria includes willingness to be randomized to receive a fat graft.
- Exclusion Criteria:
- • Age \< 18 years of age,
- • active infection,
- • medical co-morbidities or anatomic configuration deemed by the physician to be a concern for safety,
- • unwilling or unable to comply with study procedures,
- • radiation to the site of interest,
- • prisoners and/or vulnerable populations.
- • In addition, candidates that are pregnant or plan to become pregnant in the next year, will be excluded.
About University Of Pittsburgh
The University of Pittsburgh is a leading research institution known for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a robust infrastructure for research and a multidisciplinary approach, the university fosters collaboration among experts in various fields, facilitating the development of novel therapies and interventions. Its clinical trial programs emphasize ethical standards, patient safety, and the integration of cutting-edge technology, making the University of Pittsburgh a pivotal contributor to the landscape of clinical research and a trusted partner in the pursuit of health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
Francesco Egro
Principal Investigator
University of Pittsburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported